Group 1 - The company, Lijun Pharmaceutical (01513.HK), announced a share buyback plan on November 5, 2025, involving an expenditure of RMB 6 million to repurchase 164,000 A-shares [1] - The buyback price per share is set between RMB 36.41 and RMB 36.64 [1]

FF305 呈交日期： 2025年11月5日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01513 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存( ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 麗珠醫藥集團股份有限公司 呈交日期： 2025年11月4日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01513 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）變動 | 佔有關事件前的現有已發 | | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不 ...

Core Viewpoint - Lijun Pharmaceutical (01513) announced a share buyback plan, intending to repurchase 164,700 A-shares at a total cost of 5.9998 million yuan [1] Group 1 - The company plans to execute the buyback on November 4, 2025 [1] - The total expenditure for the buyback is approximately 5.9998 million yuan [1] - The number of shares to be repurchased is 164,700 [1]

Core Viewpoint - Lijun Pharmaceutical (01513.HK) announced a share buyback plan, indicating confidence in its stock value and commitment to returning capital to shareholders [1] Group 1: Buyback Details - The company plans to repurchase 164,700 A shares at a total cost of RMB 6 million [1] - The buyback price per share is set between RMB 36.16 and RMB 36.71 [1]

Core Viewpoint - Lijun Pharmaceutical (01513) announced a share buyback plan, intending to repurchase 164,700 A-shares at a cost of 5.9998 million yuan, scheduled for November 4, 2025 [1] Summary by Category - **Company Actions** - The company plans to spend 5.9998 million yuan to buy back 164,700 A-shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 FF305 公司名稱： 麗珠醫藥集團股份有限公司 呈交日期： 2025年11月4日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01513 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）變動 | 佔有關事件前的現有已發 | | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已 ...

Group 1 - The announcement pertains to the compliance inspection results of Lijun Group Fuzhou Fuxing Pharmaceutical Co., Ltd. regarding Good Manufacturing Practice (GMP) [3] - The inspection was conducted based on the Drug Administration Law and relevant regulations, with a focus on the production quality management standards [3] - The inspection covered the production lines for the raw material Vancomycin Hydrochloride, specifically the second and fourth production lines [4] Group 2 - The inspection took place from September 25 to September 27, 2025 [4] - The results indicate that the company’s production practices are compliant with the GMP standards [4] - The inspection was conducted at the company's facility located in Fuzhou, Fujian Province [4]

Market Overview - The precision medicine sector experienced a decline of 1.77% on November 4, with TuoJing Life leading the drop [1][2] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] Stock Performance - Notable stock performances in the precision medicine sector included: - RenDu Bio (688193) closed at 52.90, up 1.05% with a trading volume of 7076.23 hands and a transaction value exceeding 36.99 million yuan [1] - TuoJing Life (300642) closed at 22.73, down 2.86% with a trading volume of 78,200 hands and a transaction value of 178 million yuan [2] - Other companies like DaAn Gene (002030) and Anke Bio (300009) showed minimal changes, with DaAn Gene remaining flat at 6.57 and Anke Bio down 0.55% to 10.84 [1][2] Capital Flow - The precision medicine sector saw a net outflow of 979 million yuan from institutional investors, while retail investors contributed a net inflow of 642 million yuan [2][3] - Specific stock capital flows indicated: - GuoMai Technology (002093) had a net inflow of 8.61 million yuan from institutional investors, while retail investors saw a net outflow of 15.98 million yuan [3] - TuoJing Life experienced minimal net inflow from institutional investors at 25,000 yuan, with retail investors also showing a slight outflow [3]

Group 1: Company Insights - Yaxing Integrated (603929.SH) reported a record high quarterly profit with a significant increase in gross margin, achieving a revenue of 1.425 billion yuan in Q3 2025, down 9% year-on-year but up 68% quarter-on-quarter, and a net profit of 282 million yuan, up 40% year-on-year and 257% quarter-on-quarter [10][12] - The company’s gross margin reached 27.5% in Q3 2025, a substantial increase of 7.1 percentage points from the previous quarter and 11.0 percentage points from the same period last year, indicating improved cost control in the Singapore market [10][12] - The company is expected to continue benefiting from significant orders in the semiconductor cleanroom engineering sector, with profit forecasts for 2025-2027 adjusted to 679 million, 1.007 billion, and 1.237 billion yuan respectively, reflecting a strong growth outlook [12] Group 2: Industry Trends - The automotive industry is experiencing a surge in intelligent technology, with companies like Xiaoma Zhixing and Wenyuan Zhixing preparing for IPOs in Hong Kong, and Junsheng Electronics securing a global order worth 5 billion yuan in automotive intelligence [16][19] - The pharmaceutical sector is focusing on cardiovascular diseases, with multinational pharmaceutical companies intensifying their efforts on PCSK9 and Lp(a) targets, projecting a global market size for PCSK9 inhibitors to reach 11-19 billion USD and Lp(a) inhibitors to reach 3-7 billion USD [20][21] - The electronic gas market is expanding, driven by the demand for semiconductor manufacturing, with companies like Guanggang Gas (688548.SH) reporting a 14.85% increase in revenue year-to-date, indicating a robust growth trajectory in the electronic gas sector [24][25]